From: Estimation the medical cost of multiple sclerosis in Iran; 2019–2020
Drug Generic Name | Number of Patients received MS medications (IHIO) | Total Drug Cost (1000 $) | Copayment Share (%) | Out of Pocket (1000 $) | IHI Cost share (1000 $) | Cost Per Patient ($) | OOP per Patients ($) | Estimate of Country Total Cost (1000 $) | Share in the Total Cost (%) |
---|---|---|---|---|---|---|---|---|---|
Beta-Interferon | 21,019 | 56,280.1 | 13 | 7316.4 | 48,963.7 | 2677.5 | 348.08 | 112,560.3 | 58.53 |
Glatiramer Acetate | 1434 | 4251.1 | 10 | 425.1 | 3826.06 | 2964.5 | 296.4 | 8502.3 | 4.42 |
Dimethyl Fumarate | 8779 | 7546.4 | 30 | 2263.9 | 5282.5 | 859.6 | 257.8 | 15,092.9 | 7.84 |
Fingolimod | 7333 | 7585.4 | 5 | 379.2 | 7206.1 | 1034.4 | 51.7 | 15,170.8 | 7.88 |
Teriflunomide | 1553 | 1540.8 | 30 | 462.2 | 1078.5 | 992.1 | 297.6 | 3081.6 | 1.60 |
Rituximab | 9506 | 13,470.7 | 10 | 1347.07 | 12,123.7 | 1417.08 | 141.7 | 26,941.5 | 14.01 |
Natalizumab | 724 | 5459.05 | 10 | 545.9 | 4913.1 | 7540.1 | 754.01 | 10,918.1 | 5.67 |
Cyclophosphamide | 192 | 6.37 | 10 | 0.63 | 5.73 | 33.1 | 3.3 | 12.7 | 0.006 |
Mitoxantrone | 102 | 8.88 | 10 | 0.88 | 8 | 87.1 | 8.7 | 17.7 | 0.009 |
Total | 50,642 | 96,149.19 | 13.25 | 12,741.51 | 83,407.68 | 17,605.87 | 2159.54 | 192,298.38 | 100 |